Contact

100 North Main Street
Suite 301
Alpharetta, GA 30009

450 West 31st Street
8th Floor
New York, NY 10001

contact@avego.com
646-844-0030

Avego News

Stay informed with the latest updates from Avego and our portfolio.

June 6 2024

ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

Read more

June 6 2023

AtomVie Global Radiopharma raises over $90M to Complete its New Facility Buildout

Read more

March 3 2023

Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility

Read more

January 1 2023

PBS Biotech Raises $22M to Expand Single-Use Manufacturing Products and Services for Cell Therapy Clients

Read more

November 11 2022

Escient Pharmaceuticals Announces $120 Million Series C Financing

Read more

August 8 2022

AtomVie Global Radiopharma Inc. Announces its Spinout and Series A Financing with Avego

Read more

January 1 2022

Amneal Acquires Saol Therapeutics’ Baclofen Franchise

Read more

December 12 2021

Saol Therapeutics Announces FDA Approval of LYVISPAH™ (baclofen) Oral Granules and the Divesture of its Plasma-derived Hyperimmune Portfolio

Read more

November 11 2021

Ellie Diagnostics Raises Growth Equity from Avego Healthcare Capital

Read more

November 11 2021

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

Read more

October 10 2021

Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation

Read more

August 8 2021

Ribon Therapeutics Secures $65 Million Financing

Read more

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation

Read more

Arch Oncology Secures $105 Million Series C Financing

Read more

Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline

Read more

Santen and U.S. Ophthalmic Company Eyevance Enter into Share Purchase Agreement

Read more